Hyperpituitarism

This phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo …

This study looks at the long-term safety and effectiveness of an oral medication called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. About 43 adults who finished a previous related study will take the drug and be monitored for …

This study tests an oral drug called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. Participants had their disease under control with standard injections and were randomly assigned to receive either paltusotine or a placebo. The …

This study tests an oral drug called paltusotine in 111 adults with acromegaly, a condition causing abnormal growth due to high hormone levels. Participants are not currently on other treatments. The main goal is to see if the drug safely lowers insulin-like growth factor-1 (IGF-…

This early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…